Tenaya Therapeutics | IPO Presentation Deck | 36 slides

Tenaya Therapeutics · 2021-07
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

36
every slide · same image gating as the playbook
01
Slide 1
Features a metaphorical image of a person on a cliff edge, aligning with the 'Scaling New Heights' theme.front_matter
02
This is a standard legal slide found in IPO or investor pitch decks.other
03
Standard IPO deal terms table.summarize
04
The slide is split into two sections: Leadership (left) and Board of Directors (right).other
Open slide detailBeat · Team
05
transition
06
The slide uses a split-screen layout with text on the left and a family photo on the right, emphasizing the human impact of the company's mission.inspire_vision
07
Uses a central emotional photo of a patient to anchor the 'Why We Do What We Do' aspect.argue_timing
Open slide detailBeat · ProblemLoop · Why Now
08
The slide uses a stylized mountain/heart-shaped diagram to organize company pillars.summarize
09
The slide uses an infinity loop diagram to represent the interconnected nature of the three platforms.present_solution
Open slide detailBeat · Solution
10
The slide uses a bottom-up flow to connect capabilities to strategic outcomes (Speed, Safety, Cost, Quality, Efficacy).present_solution
Open slide detailBeat · Solution
11
The slide uses a Gantt-style visualization to show the development status of multiple drug candidates.plan_implementation
12
transition
13
The slide uses a split-screen layout to contrast the disease state (pathophysiology) with the therapeutic intervention (product concept).present_solution
Open slide detailBeat · Product
14
Includes bar chart, line chart, and Kaplan-Meier survival curve.show_traction
Open slide detailBeat · ProductLoop · Hypothesis Test
15
The slide uses bar charts with individual data points to demonstrate efficacy across three distinct physiological metrics.show_traction
Open slide detailBeat · Product
16
The slide uses a three-column layout to present histological, VCN (vector copy number), and protein expression data.present_solution
Open slide detailBeat · Product
17
The slide uses two distinct charts to show tissue specificity (bar chart) and functional efficacy (line chart with error bars).present_solution
Open slide detailBeat · Product
18
The slide uses a process flow diagram to illustrate the scaling of manufacturing capacity.plan_implementation
Open slide detailBeat · Product
19
The slide uses a two-column layout to contrast past achievements (Progress) with future goals (Next Steps).show_traction
Open slide detailLoop · Quick Win Big Bet
20
transition
21
Includes anatomical pathology image and molecular structure diagram of desmosomes.present_solution
22
Slide shows three distinct charts: a line chart for RV area, a bar chart for ejection fraction, and a Kaplan-Meier survival curve.show_traction
23
The slide compares WT, untreated PKP2-cKO (HBSS), and treated PKP2-cKO (AAV:mPKP2) using both a bar chart of arrhythmia scores and representative ECG traces.show_traction
24
The slide uses a combination of a bar chart for transduction ratios and a scatter plot for ventricular specificity to validate the efficacy of the TNC-CM seriespresent_solution
25
transition
26
Includes a biological mechanism diagram showing how HDAC6 inhibitors target multiple pathways leading to diastolic dysfunction and HFpEF.present_solution
27
The slide outlines a proprietary R&D pipeline for identifying and validating drug targets using patient-derived cells and machine learning.present_solution
28
The slide presents four bar charts comparing Control, Vehicle (disease model), and TYA-11631 (treatment) groups across four physiological metrics.show_traction
29
The slide presents three distinct charts comparing Control, Vehicle-treated HFpEF, and TYA-11631-treated HFpEF groups.show_traction
30
The slide presents three distinct sets of experimental results: glucose tolerance test, insulin sensitivity test, and inflammatory marker expression (Tgfb1, IL-show_traction
31
The slide uses a bar chart to show selectivity and a dose-response curve to show safety (thrombocytopenia risk).present_solution
32
The slide uses a two-column layout to contrast past achievements (Progress) with future goals (Next Steps).show_traction
33
transition
34
Includes a biological mechanism diagram and a line chart showing Ejection Fraction improvement in murine models.present_solution
35
The slide uses a three-column layout: Disease Overview, Product Concept, and In Vivo Data.present_solution
36
The slide uses a timeline-based table for programs and an infographic for platforms.plan_implementation